ENSG vs MDGL
Ensign Group vs Madrigal Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
MDGL
Madrigal Pharmaceuticals, Inc.
56
Watch
| Metric | ENSG | MDGL |
|---|
| AI Score |
69
|
56
|
| Price |
$180.10
|
$535.01
|
| P/E Ratio |
27.43×
|
-41.53×
|
| ROE |
15.4%
|
-47.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
91.5%
|
| Debt / Equity |
0.92×
|
0.66×
|
| Dividend Yield |
0.1%
|
0.0%
|
| RSI (14) |
71.8
|
60.0
|
| Beta |
0.694
|
-1.003
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus MDGL.
ENSG leads by 13 points.
ENSG scores 69/100 (Buy) versus MDGL at 56/100 (Watch).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
MDGL Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 149.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 21.9x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 149.0% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 21.9x prices in significant intangible value — Value
- ROE of only -56.6% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical